Читать книгу Assisted Reproduction Techniques - Группа авторов - Страница 144

1 1 Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273–88.

2 2 Saleem M, Martin H, Coates P. Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues. Clin Biochem Rev 2018; 39:3–16.

3 3 Voogt JL, Lee Y, Yang S, et al. Regulation of prolactin secretion during pregnancy and lactation. Prog Brain Res 2001; 133:173–85.

4 4 Evers JL. Female subfertility. Lancet 2002; 360:151–9.

5 5 Chen AX, Burt MG. Hyperprolactinaemia. Aust Prescr 2017; 40:220–4.

6 6 Pattinson HA, Taylor PJ, Fleetham JA, Servis SA. Transient hyperprolactinemia has no effect on endocrine response and outcome in in vitro fertilization (IVF). J In vitro Fert Embryo Transf. 1990; 7(2):89–93.

7 7 Hofmann GE, Denis AL, Scott RT, Muasher SJ. The incidence of transient hyperprolactinemia in gonadotropin‐stimulated cycles for in vitro fertilization and its effect on pregnancy outcome. Fertil Steril. 1989; 52(4):622–6.

8 8 Gonen Y, Casper RF. Does transient hyperprolactinemia during ovarian hyperstimulation interfere with conception or pregnancy outcome? Fertil Steril. 1989; 51(6):1007–10.

9 9 Piekos MW, Binor Z, Rawlins RG, Radwanska E. Effects of induced hyperprolactinemia on in vitro fertilization cycles. Fertil Steril. 1995; 63(2):371–6.

10 10 Holt RI. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 2008; 22:28–37.

11 11 Molitch ME. Drugs and prolactin. Pituitary 2008; 11:209–18.

12 12 Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med 2003; 349:2035–41.

13 13 Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265–73.

14 14 Chahal J, Schlechte J. Hyperprolactinemia. Pituitary 2008; 11:141–6.

15 15 Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853–61.

16 16 Filho RB, Domingues L, Naves L, et al. Polycystic ovary syndrome and hyperprolactinemia are distinct entities. Gynecol Endocrinol 2007; 23:267–72.

17 17 Delcour C, Robin G, Young J, et al. PCOS and Hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Health 2019; 13:1179558119871921.

18 18 Koller T, Kollerova J, Huorka M, et al. [Impact of basal prolactin levels on the prevalence of complications and the prognosis of patients with liver cirrhosis]. Vnitr Lek 2009; 55:468–73.

19 19 Kolodny RC, Jacobs LS, Daughaday WH. Mammary stimulation causes prolactin secretion in non‐lactating women. Nature 1972; 238:284–6.

20 20 Grigg J, Worsley R, Thew C, et al. Antipsychotic‐induced hyperprolactinemia: synthesis of world‐wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl) 2017; 234:3279–97.

21 21 Honegger J, Nasi‐Kordhishti I, Aboutaha N, et al. Surgery for prolactinomas: a better choice? Pituitary 2019.

22 22 PG. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 2006; 125:152–64.

23 23 Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary 2019.

24 24 Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac‐valve regurgitation. N Engl J Med 2007; 356:29–38.

25 25 Valassi E, Klibanski A, Biller BM. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010; 95:1025–33.

26 26 Steeds R, Stiles C, Sharma V, et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin Endocrinol (Oxf) 2019; 90:662–9.

27 27 Ioachimescu AG, Fleseriu M, Hoffman AR, et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin‐secreting adenomas. Eur J Endocrinol 2019; 180:31–40.

28 28 Konopka P, Raymond JP, Merceron RE, et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983; 146:935–8.

29 29 Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65:823–7.